OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice (original) (raw)
Essential role of OX40L expressed on DCs in their immunostimulatory capacity. It has previously been noted that the ability of DCs to induce T cell–mediated immunity is dependent on their maturation/activation stage, which can be triggered by a variety of factors, including inflammatory cytokines such as TNF-α (16, 17). To confirm these earlier findings, the immunogenicity of TNF-α–stimulated DCs was examined in an immunization challenge model using OVA as a model antigen. As expected, immunization of C57BL/6 mice with TNF-α–stimulated DCs pulsed with OVA markedly suppressed tumor growth of OVA-expressing EG7-OVA cells relative to control immunizations (P < 0.0001 versus all other groups; Figure 1A). The tumor-suppressive effect was well associated with the OVA-specific cytotoxic activity of splenocytes from the immunized mice; animals immunized with TNF-α–stimulated DCs pulsed with OVA caused 37% lysis of EG7-OVA target cells at an effector/target ratio of 60:1, whereas control immunized animals caused approximately 19% lysis (P < 0.01; Figure 1B). The specificity of the detected EG7-OVA lysis was confirmed by the lack of apparent lysis against EL4 cells, OVA-negative parent cells (Figure 1B).
Mice immunized with OVA-pulsed DCs in an OX40L-dependent manner. (A) Tumor growth in TNF-α–stimulated DCs. Mice were immunized with TNF-α–stimulated DCs pulsed with OVA (filled squares), DCs pulsed with OVA alone (circles), or TNF-α–stimulated DCs alone (triangles), and were challenged with EG7-OVA cells (day 0). Mice without any immunization (open squares) were used as controls. (B) OVA-specific cytotoxicity in TNF-α–stimulated DCs. Eight days after the immunization described in A, splenocytes were isolated and assayed for cytolytic function by using EG7-OVA or EL4 cells as target cells. (C and D) Flow cytometric analysis of TNF-α–stimulated DCs. DCs from wild-type or OX40L–/– mice were stimulated with TNF-α and analyzed 2 days later for OX40L (C) or CD80 expression (D). Overlay (filled) histograms depict naive DCs. The percentages of stained cells above isotype control staining are shown in each panel. (E) Role of OX40L on DCs and in tumor growth. TNF-α–stimulated OX40L–/– (circles) or wild-type DCs (filled squares) pulsed with OVA were used for the immunization challenge experiment. (F) Role of OX40L on DCs and OVA-specific cytotoxic T cells. Ten days after the immunization described in E, splenocytes were isolated and analyzed for OVA-reactive CD8+ T cells (CD8+H-2Kb/SIINFEKL pentamer+, boxed) by flow cytometry. The percentage of positive cells is listed. (G and H) Flow cytometric analysis of AdOX40L-modified DCs. DCs were transduced with AdOX40L or AdNull and analyzed 2 days later for OX40L (G) or CD80 expression (H). The percentages of stained cells above isotype control staining are shown in each panel. (I) Tumor growth in AdOX40L-modified DCs. AdOX40L- (circles) or AdNull-modified DCs (triangles) pulsed with OVA were used for the immunization challenge experiment. (J) OVA-specific cytotoxicity of AdOX40L-modified DCs. Eight days after the immunization described in I, splenocytes were assayed for cytolytic function.
We next investigated the expression of surface markers characteristic of DC maturation and/or activation on TNF-α–stimulated DCs (Figure 1, C and D, and Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI32693DS1). Our results showed that, compared with naive DCs, TNF-α–stimulated DCs had an increase in the number of positive cells for all surface markers examined, and especially exhibited a marked increase of OX40L expression (OX40L, 24% versus 48%; CD54/ICAM-1, 70% versus 81%; CD70, 8% versus 22%; CD80/B7-1, 35% versus 49%; CD86/B7-2, 26% versus 37%; CD137L/4-1BBL, 7% versus 10%).
Thus, the role of OX40L for the induced specific cellular immune response was examined using DCs prepared from OX40L–/– mice for the immunization (Figure 1E). Even when stimulated with TNF-α and pulsed with OVA, OX40L–/– DCs provided no protection against the subsequent EG7-OVA tumor challenge, whereas wild-type DCs showed complete protection (P < 0.01, OX40L–/– DCs versus wild-type DCs; Figure 1E). The antitumor effect of the DC/TNF-α/OVA immunization was related to the appearance of OVA-reactive CD8+ T cells in splenocytes from the immunized mice (Figure 1F and Supplemental Figure 2). In this context, the DC/TNF-α/OVA immunization protocol using wild-type DCs induced significant expansion of CD8+H-2Kb/OVA pentamer+ T cells compared with that in OX40L–/– DCs (P < 0.005 versus all other immunization protocols; Figure 1F and Supplemental Figure 2). Although our results showed that OX40L–/– DCs lost the ability to induce antigen-specific cellular immune responses, we found no difference in the surface expression of phenotypic markers between wild-type and OX40L–/– DCs except for OX40L (OX40L, wild-type 48% versus OX40L–/– 0%; CD54, wild-type 81% versus OX40L–/– 84%; CD70, wild-type 22% versus OX40L–/– 23%; CD80, wild-type 49% versus OX40L–/– 48%; CD86, wild-type 37% versus OX40L–/– 34%; CD137L/4-1BBL, wild-type 10% versus OX40L–/– 11%; Figure 1, C and D, and Supplemental Figure 1).
We therefore hypothesized that only the increased expression of OX40L on DCs would be sufficient to improve their immunostimulatory capacity. To evaluate this concept, we used an E1– adenovirus (Ad) gene transfer vector expressing OX40L cDNA (AdOX40L) to genetically modify DCs, and confirmed that AdOX40L modification of DCs enhanced the expression of OX40L, but did not affect other DC-lymphocyte costimulatory molecules compared with control AdNull modification (OX40L, AdOX40L 72% versus AdNull 45%; CD54, AdOX40L 44% versus AdNull 43%; CD80, AdOX40L 29% versus AdNull 31%; CD86, AdOX40L 19% versus AdNull 18%; Figure 1G and data not shown).
Using the AdOX40L-modified DCs, we examined whether DCs genetically modified to express OX40L alone could efficiently induce antigen-specific cellular immunity. Immunization of mice with AdOX40L-modified DCs pulsed with OVA before EG7-OVA tumor challenge resulted in a significant slowing of the tumor growth relative to control immunizations (P < 0.001 versus all other groups; Figure 1I). Consistent with this finding, effector cells from mice immunized with AdOX40L-modified DCs pulsed with OVA exhibited an apparent lysis of EG7-OVA target cells, but not EL4 target cells (Figure 1J). These data indicate that genetic modification of DCs to express OX40L enabled DCs to develop the effective antigen-specific cellular immunity underlying the antitumor effects in the immunization challenge experiments.
DCs modified to express OX40L elicit therapeutic immunity against preexisting tumors. To further examine the immunostimulatory potential of the AdOX40L-modified DCs, we tested the idea of suppressing the growth of preexisting tumors by direct administration of these cells. In these experiments, we injected AdOX40L- or AdNull-modified DCs into B16-F10 tumors established for 8 days in C57BL/6 mice and found a significant growth suppression of tumors treated with AdOX40L-modified DCs (P < 0.05 versus all other groups; Figure 2A). Moreover, marked cytolytic activity against B16-F10 tumor cells was also observed in mice treated with AdOX40L-modified DCs, whereas only minimal cytolytic activity was observed in control mice (Figure 2B). As a control for the specificity of the cytolytic activity, no apparent lysis was detected against irrelevant Lewis lung carcinoma (LLC) cells (Figure 2B). Similar results were obtained in the Colon-26 tumor model in BALB/c mice (data not shown).
Tumor-bearing mice treated with intratumoral administration of AdOX40L-modified DCs. (A) Tumor growth. B16-F10 tumor–bearing mice were treated by intratumoral injection of DCs modified with AdOX40L (circles) or AdNull (triangles). Tumor-bearing mice without any treatment (squares) were used as controls. (B) Tumor-specific cytotoxic T cell response. Ten days after the treatment described in A, splenocytes were isolated and then assayed for cytolytic function by using B16-F10 or LLC cells as target cells. (C) Immunohistochemical evaluation of tumors’ CD4+ and CD8+ cells. Three days after the treatment described in A, the tumors were dissected, and the frozen tumor sections were stained with anti-CD4 or anti-CD8 antibodies. Numbers at bottom right of each panel denote the number of positive cells per 10 random high-power fields (original magnification, ×400). (D) Role of CD4+ and CD8+ T cells in tumor growth. The study was similar to that in A, but CD4+ T cell–/– (circles), CD8+ T cell–/– (triangles) or wild-type mice (blue squares) bearing B16-F10 tumors were treated with AdOX40L-modified DCs. (E) Role of CD4+ and CD8+ T cells in tumor-specific cytotoxic T cell response. Ten days after the treatment as in D, splenocytes were isolated and assayed for cytolytic function. (F) Role of OX40 on CD4+ T cells and in tumor growth. The study was similar to that in D, but the CD4+ T cell–/– mice were reconstituted with OX40–/– (circles) or wild-type CD4+ T cells (triangles) 1 day before the treatment.
Next, we performed immunohistochemical analysis to delineate the immunological mechanisms that mediate the antitumor effect of AdOX40L-modified DCs. Our data demonstrated that AdOX40L-modified DCs injected into established subcutaneous tumors enhanced the intratumoral infiltration of both CD4+ T cells and CD8+ T cells compared with control tumors (CD4+ T cells per 10 high-power fields, AdOX40L DCs 628, AdNull DCs 206, no treatment 153; CD8+ T cells per 10 high-power fields, AdOX40L DCs 184, AdNull DCs 52, no treatment 64; Figure 2C). Accordingly, we examined the role of CD4+ T cells and CD8+ T cells in the antitumor responses; B16-F10 tumors established in wild-type, CD4–/–, or CD8–/– C57BL/6 mice were treated by intratumoral injection with AdOX40L-modified DCs. In marked contrast to the tumor suppression of treated wild-type mice, tumors in CD4–/– and CD8–/– mice were not diminished by the treatment of AdOX40L-modified DCs (P < 0.005, CD4–/– and CD8–/– versus treated wild-type; Figure 2D). The relevance of the in vivo tumor suppression to the in vitro tumor lysis was demonstrated by showing that the intratumoral treatment of B16-F10 tumor–bearing mice with AdOX40L-modified DCs enhanced the cytolytic activity specific for B16-F10 cells in wild-type mice, but not in CD4–/– or CD8–/– mice (Figure 2E).
OX40, a sole receptor for OX40L, is generally considered to be implicated in CD4+ T cell–mediated adaptive immunity, based on evidence that OX40 is expressed primarily on CD4+ T cells and that its engagement is required for effective priming of CD4+ T cells (3–5, 20–31). Therefore, to evaluate the contribution of OX40 on host CD4+ T cells to tumor-suppressive immunity, we reconstituted B16-F10 tumor–bearing CD4–/– mice by adoptively transferring CD4+ T cells from wild-type or OX40–/– mice before the intratumoral administration of AdOX40L-modified DCs. Strikingly, the reconstitution of wild-type CD4+ T cells into CD4–/– recipient mice restored the ability of the AdOX40L/DC treatment to enhance the antitumor immunity compared with treated wild-type mice, but that of OX40–/– CD4+ T cells did not (P < 0.001, wild-type versus OX40–/–; Figure 2F). These findings indicate that, consistent with the current concept of OX40-OX40L interactions in effective CD4+ T cell responses, OX40L-expressing DCs induce the antigen-specific immunity through the OX40 engagement on CD4+ T cells.
Requirement of NKT cells for antitumor immunity generated by OX40L-expressing DCs. Further immunohistochemical analysis of the tumor treated with AdOX40L-modified DCs showed an increased number of tumor-infiltrating OX40+ cells compared with control tumors (OX40+ cells per 10 high-power fields, AdOX40L DCs 481, AdNull DCs 104, no treatment 93; Figure 3A). To characterize the OX40+ cells infiltrating the AdOX40L/DC-treated tumor, we stained these OX40+ cells with α-GalCer–loaded CD1d dimer, because CD1d molecules loaded with α-GalCer have been used to specifically detect NKT cells in vivo (32, 33). Notably, 20% of the infiltrating OX40+ cells bound CD1d/α-GalCer dimer (Figure 3B), indicating that the intratumoral treatment of AdOX40L-modified DCs promotes the infiltration of OX40-expressing NKT cells at this site. This was confirmed by detecting the intratumoral infiltration of CD3+OX40+CD1d/α-GalCer dimer+ cells in wild-type mice, which was not observed in NKT cell–/– mice (Supplemental Figure 3). We therefore examined the number of intratumoral NKT cells and observed a marked increased in the tumors treated with AdOX40L-modified DCs compared with control tumors (3- to 7-fold increase; P < 0.05; Figure 3C).
Involvement of NKT cells in the therapeutic effect elicited by intratumoral administration of AdOX40L-modified DCs. (A) Immunohistochemical evaluation of tumors for OX40+ cells. Three days after injection of AdOX40L- or AdNull-modified DCs to B16-F10 tumors, frozen sections of the tumors were stained with anti-mouse OX40 antibody. Numbers at bottom right denote the number of positive cells per 10 random high-power fields (original magnification, ×400). Untreated tumors were used as controls. (B) OX40+CD1d/α-GalCer dimer+ cells. OX40+ cells from tumors treated with AdOX40L-modified DCs were analyzed for the CD1d/α-GalCer dimer binding by flow cytometry. Overlay (filled) histogram depicts OX40+ cells stained without dimer. The percentage of CD1d/α-GalCer dimer+ cells above control staining is shown. (C) Quantification of intratumoral NKT cells. The number of CD1d/α-GalCer dimer+ NKT cells in tumors treated as in A was determined by flow cytometry. (D and E) Role of NKT cells. NKT cell–/– (circles) or wild-type mice (triangles) bearing B16-F10 tumors were treated with AdOX40L-modified DCs. Tumor-bearing wild-type mice without any treatment (squares) were used as controls. (F and G) Role of OX40 on NKT cells. The NKT cell–/– mice were reconstituted with OX40–/– (circles) or wild-type NKT cells (triangles) 1 day before the treatment. (H and I) Role of CD1d on DCs. CD1d–/– (circles) or wild-type DCs (triangles) were used to prepare AdOX40L-modified DCs for the treatment. (D, F, and H) The size of each tumor was assessed to evaluate tumor growth. (E, G, and I) At 10 days after treatment, splenocytes were isolated and assayed for cytolytic function using B16-F10 or LLC cells as target cells.
These findings prompted us to test whether host NKT cells are required for the tumor-specific immunity developed by the AdOX40L/DC treatment. We found that the B16-F10 tumor size treated with AdOX40L-modified DCs was remarkably suppressed in wild-type mice but not in NKT cell–/– mice (P < 0.001, NKT cell–/– versus wild-type; Figure 3D). In line with the in vivo data on tumor growth, splenocytes from B16-F10 tumor–bearing NKT cell–/– mice treated with AdOX40L-modified DCs exhibited no cytolytic activity regardless of the type of target cells, parent B16-F10 cells or irrelevant LLC cells, whereas splenocytes from B16-F10 tumor–bearing wild-type mice treated with the same regimen exhibited a specific lysis of B16-F10 (Figure 3E). The failure of NKT cell–/– mice to develop the AdOX40L/DC-mediated cellular immunity indicates that NKT cells represent an essential cell compartment for the developed immunity.
It was recently reported that blockage of OX40L on DCs with anti-OX40L blocking antibody inhibited the cells’ ability to support NKT cell activation (34). Therefore, to extend our finding of surface OX40 expression on NKT cells (Figure 3B), we examined more closely the contribution of OX40 on NKT cells to the cellular immunity afforded by the AdOX40L/DC treatment. In these experiments, B16-F10 tumor–bearing NKT cell–/– mice were reconstituted with NKT cells isolated from wild-type mice or OX40–/– mice before the intratumoral administration of AdOX40L-modified DCs. Although NKT cell–/– mice reconstituted with wild-type NKT cells responded to the AdOX40L/DC treatment with a noticeable suppression of tumor growth, reconstitution with OX40–/– NKT cells failed to restore the responsiveness (P <_ 0.01, wild-type versus OX40–/–; Figure 3F). Similar results were also achieved in the treatment using DCs pulsed with α-GalCer, although the tumor-suppressive effect of α-GalCer–pulsed DCs was partially comparable to that of AdOX40L-modified DCs (days 8–19; _P > 0.1, AdOX40L-modified DCs versus α-GalCer-pulsed DCs, Supplemental Figure 4A; P < 0.05, wild-type NKT versus OX40–/– NKT, Supplemental Figure 4B). This failure of reconstitution with OX40–/– NKT cells in the tumor-suppressive effect of the AdOX40L/DC treatment was paralleled by the tumor-specific cytolytic activity present in the spleens of treated mice (Figure 3G). With the intratumoral administration of AdOX40L-modified DCs to established B16-F10 tumors, the B16-F10–specific cytolytic response was observed in splenocytes from NKT cell–/– mice that had been reconstituted with wild-type NKT cells, but not OX40–/– NKT cells (Figure 3G). Our studies indicate that the development of tumor-specific cellular immunity after the AdOX40L/DC treatment requires NKT cells, especially OX40 on NKT cells of the tumor-bearing host.
Because the majority of NKT cells are thought to be restricted to CD1d-mediated antigen recognition (11, 12), we next evaluated the role of CD1d antigen presentation by DCs in the AdOX40L/DC treatment strategy. When modified with AdOX40L and administered intratumorally to preexisting B16-F10 tumors in wild-type mice, DCs obtained from CD1d–/– mice failed to exert an antitumor effect on the growth, which was significantly different from the result with DCs from wild-type mice (P < 0.05, CD1d–/– versus wild-type; Figure 3H). This abrogation of the AdOX40L/DC-mediated tumor suppression correlated with the tumor-specific cytolytic activity primed in vivo (Figure 3I). That is, splenocytes from B16-F10 tumor–bearing mice treated with CD1d–/– DCs displayed roughly 3-fold less cytotoxicity against parental B16-F10 target cells at an effector/target ratio of 60:1 than did splenocytes from mice treated with wild-type DCs (Figure 3I). These results show the requirement of CD1d-dependent antigen presentation by OX40L-engineered DCs for their immunostimulatory capacity, suggesting that OX40L-expressing DCs directly interact with CD1d-restricted NKT cells for the OX40-mediated costimulation.
Infiltrating NKT cells serve as a local source of IFN-γ. Given the observed link of NKT cells to the tumor-suppressive cytotoxic T cell activation of the AdOX40L/DC treatment, and given the notion that the secretion of cytokines by NKT cells influences several aspects of the immune responses (11, 13), we examined the intratumoral levels of IFN-γ, a potent stimulator of cell-mediated immunity, and their association with NKT cells. We injected B16-F10 established tumors with AdOX40L- or AdNull-modified DCs and, 5 days following the injection, measured the concentration of intratumoral IFN-γ. In wild-type mice, the IFN-γ levels of the AdOX40L/DC-treated tumors were increased approximately 2-fold compared with those of AdNull/DC-treated and untreated tumors (P < 0.0001; Figure 4A). Increased levels of intratumoral IFN-γ were not detected in NKT cell–/– mice despite the AdOX40L/DC treatment (P < 0.0001 versus AdOX40L/DC-treated wild-type, Figure 4A), indicating that the in vivo administration of AdOX40L-modified DCs locally stimulates IFN-γ production in an NKT cell–dependent manner. Consistent with this, CD1d/α-GalCer dimer+ cells (i.e., NKT cells) constituted 73% of IFN-γ+ cells in the AdOX40L/DC-treated B16-F10 tumors as assessed by flow cytometry, but less than 2% in control tumors (Figure 4B). Collectively, these in vivo findings suggest that when delivered intratumorally, DCs modified to express OX40L stimulate NKT cells to secrete IFN-γ in the local milieu and thereby potentiate Th1 and CD8+ cytotoxic T cell responses that are necessary for effective antitumor immunity.
IFN-γ production of NKT cells in tumors treated with AdOX40L-modified DCs. (A) IFN-γ levels in tumors. Five days after intratumoral injection of AdOX40L-modified DCs to 8-day established B16-F10 tumors in wild-type or NKT cell–/– mice, the tumors were dissected, and the IFN-γ levels in the tumor homogenates were measured by ELISA. Tumor-bearing mice treated with AdNull-modified DCs as well as those without any treatment were used as controls. (B) IFN-γ+CD1d/α-GalCer dimer+ cells in tumors. A single-cell suspension was prepared from the B16-F10 tumors treated as in A, and the IFN-γ+ cells were analyzed for the CD1d/α-GalCer dimer binding by flow cytometry. Overlay (filled) histogram depicts IFN-γ+ cells stained without dimer. The percentages of CD1d/α-GalCer dimer+ cells above control staining are shown in each panel.
OX40 engagement on NKT cells contributes to their activation status. To investigate more clearly the immunological event of OX40-dependent NKT cell activation without confounding effects that might be caused by the intratumoral administration of genetically modified DCs, we examined the ability of α-GalCer to stimulate NKT cells in OX40–/– mice to produce IFN-γ in vivo and in vitro. Consistent with our knowledge that α-GalCer is a selective ligand that stimulates NKT cell functions such as IFN-γ production (14, 15), we found that intravenous administration of α-GalCer rapidly induced the production of IFN-γ in wild-type mice but not in NKT cell–/– mice (Figure 5A). OX40–/– mice also produced IFN-γ in response to the in vivo administration of α-GalCer, albeit at significantly lower levels than did wild-type mice (P < 0.05; Figure 5A). Similar results were obtained in the culture of spleen cells with α-GalCer (Figure 5B). When cultured in vitro with α-GalCer, spleen cells from OX40–/– mice as well as wild-type mice produced strikingly elevated levels of IFN-γ in the culture supernatants, although the increased amount of IFN-γ observed in OX40–/– spleen cells was significantly less than that observed in wild-type control spleen cells (P < 0.05; Figure 5B). Spleen cells from NKT cell–/– mice did not produce detectable level of IFN-γ despite the addition of α-GalCer. These data suggest that the α-GalCer–mediated activation of NKT cells depends in part on the triggering of their OX40.
NKT cell activation in an OX40-dependent manner. (A) IFN-γ in serum. Wild-type, OX40–/–, or NKT cell–/– mice were injected intravenously with α-GalCer or vehicle. The levels of IFN-γ were determined in serum by ELISA. (B) IFN-γ in splenocyte culture. Splenocytes were isolated from wild-type, OX40–/–, or NKT cell–/– mice and cultured with α-GalCer or vehicle. The levels of IFN-γ in the culture medium were assayed by ELISA. (C) IFN-γ in splenocyte coculture. Splenocytes from NKT cell–/– mice were cocultured with NKT cells isolated from wild-type or OX40–/– mice in the presence of α-GalCer. Where indicated, anti-CD1d antibody or control IgG was added at the initiation of the coculture. The levels of IFN-γ were assayed by ELISA. (D) CD69 on NKT cells in splenocyte coculture. The study was similar to that in C, but at the end of coculture, NKT cells were analyzed for the surface expression of CD69 by flow cytometry. Overlay (filled) histograms depict NKT cells cocultured in the absence of α-GalCer as a control. The percentages of stained cells above isotype control staining are shown in each panel.
We therefore extended this observation and confirmed the role of OX40 on NKT cells in their activation. To this end, NKT cells from wild-type mice or OX40–/– mice were cocultured in vitro with spleen cells from NKT cell–/– mice in the presence of α-GalCer and assessed for their IFN-γ responses to α-GalCer. When cocultured with NKT cell–/– splenocytes (containing CD1d-expressing antigen-presenting cells), NKT cells from OX40–/– mice, compared with NKT cells from wild-type mice, produced significantly reduced amounts of IFN-γ in response to α-GalCer (P < 0.001; Figure 5C). Similar results were achieved in the blockade of OX40/OX40L interactions with anti-OX40L antibody (P < 0.005 versus control IgG; Supplemental Figure 5). We observed no detectable amounts of IFN-γ in either wild-type or OX40–/– NKT cell culture alone (data not shown), eliminating the possibility that other immune effectors contaminating the NKT cell preparations could be responsible for the IFN-γ production observed in the coculture experiment. Moreover, these IFN-γ responses were dependent on CD1d-restricted NKT cell reactivity, because they were blocked by the addition of anti-CD1d antibody to prevent the interaction between NKT cells and CD1d-bearing splenocytes (P < 0.0001, anti-CD1d versus control IgG for both wild-type and OX40–/– NKT; Figure 5C). In parallel, we examined the degree of NKT cell activation as assessed by the expression of the CD69 activation marker on NKT cells cocultured with NKT cell–/– splenocytes. CD69 expression was upregulated on NKT cells from OX40–/– mice as well as those from wild-type mice in response to in vitro stimulation with α-GalCer, although the percentage of CD69+ cells in OX40–/– NKT cells cultured even in the presence of α-GalCer was lower than that in wild-type NKT cells cultured in the absence of α-GalCer (wild-type NKT, 62% to 84%; OX40–/– NKT, 43% to 58%; Figure 5D). Thus, the results show that OX40 on NKT cells contributes to their activation status regardless of the α-GalCer stimulation, and the involvement of OX40 becomes more apparent under conditions in which NKT cells are stimulated by CD1d-mediated recognition of α-GalCer.